Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 560-564, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bolze, S.
Right arrow Articles by Boulieu, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bolze, S.
Right arrow Articles by Boulieu, R.
Related Collections
Right arrow Animal Clinical Chemistry
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 1998;44:560-564.)
© 1998 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

HPLC determination of ketamine, norketamine, and dehydronorketamine in plasma with a high-purity reversed-phase sorbent

Sébastien Bolze1,2, and Roselyne Boulieu1,2,a

1 Université Claude Bernard Lyon 1, Institut des Sciences Pharmaceutiques et Biologiques (ISPB), Département de Pharmacie Clinique, de Pharmacocinétique et d'Evaluation du Médicament, 8 ave. Rockefeller, 69373 Lyon Cedex 08, France.

2 Hôpital Cardiovasculaire et Pneumologique, Service Pharmaceutique, B.P. Lyon Montchat, 69394 Lyon Cedex 03, France.
a Author for correspondence. Fax 04.78.77.71.58.

We developed an isocratic, selective, and very sensitive HPLC method for the determination of ketamine and its two main metabolites in plasma. The compounds were extracted from plasma by a liquid–liquid extraction with a dichloromethane:ethyl acetate mixture followed by an acidic back-extraction. Separation was achieved on a new stationary phase, Purospher RP-18 end-capped, with a mobile phase containing acetonitrile:0.03 mol/L phosphate buffer (23:77 by vol) adjusted to pH 7.2. Because of the high column efficiency and the significant improvement of peak symmetry, the quantification limit could be down to 5 µg/L for ketamine and norketamine (NK). The intraday and interday CVs ranged from 1.7% to 5.8% and 3.1% to 10.2% for all compounds respectively. The method is sensitive enough for monitoring ketamine, NK, and dehydroketamine in plasma during pharmacokinetic studies after an intravenous bolus of a low dose of ketamine.




The following articles in journals at HighWire Press have cited this article:


Home page
 Drug Metab. Dispos.Home page
S. C. Turfus, M. C. Parkin, D. A. Cowan, J. M. Halket, N. W. Smith, R. A. Braithwaite, S. P. Elliot, G. B. Steventon, and A. T. Kicman
Use of Human Microsomes and Deuterated Substrates: An Alternative Approach for the Identification of Novel Metabolites of Ketamine by Mass Spectrometry
Drug Metab. Dispos., August 1, 2009; 37(8): 1769 - 1778.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
Y. Sato, E. Kobayashi, Y. Hakamata, M. Kobahashi, T. Wainai, T. Murayama, M. Mishina, and N. Seo
Chronopharmacological studies of ketamine in normal and NMDA {epsilon}1 receptor knockout mice{dagger}
Br. J. Anaesth., June 1, 2004; 92(6): 859 - 864.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
Y. Hijazi, C. Bodonian, M. Bolon, F. Salord, and R. Boulieu
Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury
Br. J. Anaesth., February 1, 2003; 90(2): 155 - 160.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Hijazi and R. Boulieu
Contribution of CYP3A4, CYP2B6, and CYP2C9 Isoforms to N-Demethylation of Ketamine in Human Liver Microsomes
Drug Metab. Dispos., July 1, 2002; 30(7): 853 - 858.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
Y. Hijazi, M. Bolon, and R. Boulieu
Stability of Ketamine and Its Metabolites Norketamine and Dehydronorketamine in Human Biological Samples
Clin. Chem., September 1, 2001; 47(9): 1713 - 1715.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.